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Cancer  and Diagnostics Market
• Cancer is still the 2nd leading cause of 
death world wide.
• Total US costs for cancer treatment $129B 
(NIH estimate)
• Number of Americans diagnosed with 
• “A key challenge in cancer control and 
prevention is detection of the disease as 
early as possible…”    P. Srinivas
• Since an effective way to cure cancers has 
not been found, early detection becomes 
an important alternative. 
cancer each year is 1.5M
• Each year over 500,000 people in the US 
die from cancer (one every minute)
• Lung, colorectal, breast and prostrate 
account for 53% of all cancer deaths
• Cancer Diagnostics worldwide market 
estimated at $7.4B in 2009
• Tumor marker segment expected to reach 
$2B by 2010 and grow at 8-10% into the 
foreseeable future
• PSA marker for prostrate cancer alone 
accounts for $400M
Introduction
• Research Goal
– To develop a rapid, sensitive non-invasive technique 
to detect biomarkers that indicate whether or not an 
individual has cancer at the earliest possible point
– Biomarkers are compounds in the body that can be 
indicative of medical conditions or biological states. 
• Examples
– Tumors
– Proteins & peptides
– Hormones
– Small molecules
– DNA
Pteridines
• Pteridines:A group of heterocyclic compounds containing a 
wide variety of substitutions on the basic compound pterin
• Pteridine: A class of compounds excreted in the urine, whose levels 
are found to elevate significantly in tumor related diseases
• Pteridines are believed to exist in the body in predetermined levels 
that are indicative of a healthy individual. We hypothesize that  
changes in these  levels indicate that the body was being attacked by 
cancer.
• Different cancer types are believed to give unique fingerprints that 
differ from a non-cancer patient and will even provide fingerprints 
whose levels will correlate with the severity of the cancer in the body.
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Features of the Instrumental Design
• Due to the unique design of the instrument, it 
has:
– Very high sensitivity
• ~1.0 x10-11M (detection limit)
– Good reproducibility
• < 8% RDS for multiple injections over multiple days 
– Low noise
• < 1mV
• Easy to operate
• Can be upgraded for automatic analysis and 
data output
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1) 6,7-dimethylpterin
2) 6-biopterin
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Final Parameters
pH: 9.63±0.02
EP: 26kV
1 to 10: Breast Cancer Urine Samples
11 to 29: Normal Urine Samples
1 to 11: Lung Cancer Urine Samples
12 to 29:  Normal Urine Samples
Cancers we have studied
Breast Cancer
Breast Cancer with Mets
Lung Cancer
Fallicular Lymphoma
Colon Cancer
Ovarian Cancer
Non Hodgkin's Lymphoma
Rectal Cancer
Bladder Cancer
1 to 38 All 11 Cancer Urine Samples we have studied
39 to 55 Normal Urine Samples
Pancrate Cancer
Esophageal Cancer
1 to 38 All 11 Cancer Urine Samples
39 to 55 Normal Urine Samples
Series 01 : Isoxanthopterin Series 02 : Xanthopterin
1. 6,7-Dimethylpterin, 2. 6-Biopterin, 3. Neopterin, 4. Hydroxymethylpterin, 
Nov 19, 2005 Standard, Cancer, Non-Cancer Urine for Pteridine Study
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1. 6,7-Dimethylpterin, 2. 6-Biopterin, 3. Neopterin, 4. Hydroxymethylpterin,
5. Pterin, 6. Isoxathopterin, 7. Xanthopterin
Nov. 21, 2005 Standard, Cancer, Non-Cancer Urine for Pteridine Study
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• Oncopterin – It has presented itself as a 
potential indicator for a positive / negative test 
for cancer.  
– It was discovered that only oncopterin was 
observed in cancer patients where it was not 
detectable in normal people.
– We plan to synthesize the oncopterin at Missouri 
S&T and test both control and patient samples for 
the presence of this new discovery.
1. A specific instrument for pteridines
screening
2. Three solution kits for the screening 
Current system achieves these goals
process
3. One quick method for giving an “yes” or 
“no” answer based the detectable 
oncopterin.
Current Status
• We are collaborating with Dr. Anthony 
Kaczmarek (Urologist) to conduct further 
research to find finger prints for each 
cancer.
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